Brind.
  1. A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
  2. Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.
  3. A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
  4. Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.

A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.

6 reports, 1 independent Updated Aug 23
Gone quiet
Reports
6
Developments
3
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.

Who's involved

What this event is mainly about
MicrosoftDatabricksGenmab

How it developed

Newest first. Tap a step to see who reported it.
  1. Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications.Sub-event
  2. Partnership accelerates therapeutic discovery and development.1 source
  3. Strategic partnerships accelerate Tevogen's progress.1 source

Keep exploring

Part of

Microsoft, Tevogen Bio Holdings Inc., and Databricks are collaborating to build the PredicTcell model for oncology applications. All 1 developments

Within A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireTevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “
  • GlobeNewswireRepeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunitie
  • GlobeNewswireREPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Compa
  • GlobeNewswireTevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nas
  • GlobeNewswireTevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”
  • GlobeNewswireTevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market f